Compound rifaximin uterus injectant as well as preparation method and application thereof

A technology of rifaximin and injection agent, applied in the field of antibiotics and preparation thereof, can solve the problem that the drug effect needs to be further enhanced, and achieve the effects of significant treatment effect, reduction of economic loss and simple preparation method.

Inactive Publication Date: 2015-05-06
TIANJIN ZHONGSHENG TIAOZHAN BIOTECH
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But in the treatment of metritis, its efficacy needs to be further enhanced

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound rifaximin uterus injectant as well as preparation method and application thereof
  • Compound rifaximin uterus injectant as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] A compound rifaximin uterine injection, each component is calculated by weight percentage: 1% rifaximin, 5% ceftiofur crystal free acid, 2% surfactant, 0.2% antioxidant, and the balance is An oil phase, wherein the surfactant is glyceryl monostearate, the antioxidant is phenol, and the oil phase is soybean oil.

[0023] The preparation method of the above compound rifaximin uterine injection, the specific preparation steps are as follows:

[0024] (1) Accurately weigh surfactant, oil phase, rifaximin, ceftiofur crystal free acid and antioxidant according to the formula ratio, and set aside;

[0025] (2) Heat the oil phase to 100°C, add the formulated amount of surfactant and antioxidant into the oil phase, and stir to dissolve it;

[0026] (3) After returning to room temperature in (2), pour it into the colloid mill, add the formula amount of rifaximin and ceftiofur crystal free acid, and grind it circularly for 30 minutes;

[0027] (4) Filling, the drug specification...

Embodiment 2

[0029] A compound rifaximin uterine injection, each component is calculated by weight percentage: rifaximin 0.8%, ceftiofur crystal free acid 5.2%, surfactant 2%, antioxidant 0.3%, and the balance is Oil phase, wherein, the surfactant is glyceryl monostearate, the antioxidant is VE oil, and the oil phase is soybean oil.

[0030] The preparation method of the above compound rifaximin uterine injection, the specific preparation steps are as follows:

[0031] (1) Accurately weigh surfactant, oil phase, rifaximin, ceftiofur crystal free acid and antioxidant according to the formula ratio, and set aside;

[0032] (2) Heat the oil phase to 95°C, add the formulated amount of surfactant and antioxidant into the oil phase, and stir to dissolve it;

[0033] (3) After returning to room temperature in (2), pour it into a colloid mill, add the prescribed amount of rifaximin and ceftiofur crystalline free acid, and grind it circularly for 30 minutes to obtain the product.

Embodiment 3

[0035] A compound rifaximin uterine injection, each component is calculated by weight percentage: 1.2% rifaximin, 4.8% ceftiofur crystal free acid, 1.8% surfactant, 0.2% antioxidant, and the balance is An oil phase, wherein the surfactant is aluminum stearate, the antioxidant is BHA (butyl hydroxyanisole), and the oil phase is cottonseed oil.

[0036] The preparation method of the above compound rifaximin uterine injection, the specific preparation steps are as follows:

[0037] (1) Accurately weigh surfactant, oil phase, rifaximin, ceftiofur crystal free acid and antioxidant according to the formula ratio, and set aside;

[0038] (2) Heat the oil phase to 90°C, add the formulated amount of surfactant and antioxidant into the oil phase, and stir to dissolve it;

[0039] (3) After returning to room temperature in (2), pour it into the colloid mill, add the formula amount of rifaximin and ceftiofur crystal free acid, and grind it circularly for 30 minutes;

[0040] (4) Filling...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a compound rifaximin uterus injectant as well as a preparation method and application thereof. The compound rifaximin uterus injectant comprises the following components in percentage by weight: 0.8%-1.2% of rifaximin, 4.8%-5.2% of ceftiofur crystal free acid, 1.8%-2.5% of surface active agents, 0.2%-0.3% of antioxidants and the balance of oil phases, wherein the surface active agents are one or any mixture of two of glycerin monostearate, aluminum stearate and ethyl cellulose, the antioxidants are one or any mixture of two of BHA, VE oil, BHT and phenol, and the oil phases are one or any mixture of two of soybean oil, castor oil and cotton seed oil. The compound rifaximin uterus injectant provided by the invention is prepared through a mixing dissolution mode and achieves more outstanding treatment effect on bacterial endometritis.

Description

technical field [0001] The invention relates to an antibiotic and its preparation method and application, in particular to a compound rifaximin uterine injection and its preparation method and application. Background technique [0002] Metritis is one of the most common diseases of dairy cows. It is very harmful and has a high incidence rate, accounting for about 15-30% of dairy cow diseases. According to statistics, the incidence of metritis in dairy cows within 10 days after delivery is 20%-40%. The incidence rate can reach more than 80%. Metritis is one of the main reasons for repeated infertility and low reproductive rate of dairy cows. In severe cases, the environment in the uterus is damaged, endocrine disorders, easy to cause no estrus or irregular estrus, resulting in embryo death or abortion, and secondary mastitis, Laminitis, etc., seriously restrict the development of the dairy industry. [0003] The etiology of dairy cow endometritis is complex, mainly includin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/546A61P15/00A61P29/00A61P31/04A61K31/439
Inventor 甄盼盼王建焦晓军王猛程雪娇王勇余贵菊朱士江季坤李丽琴姜淋洁张立会崔志刚杨雪王宇鹏李玲
Owner TIANJIN ZHONGSHENG TIAOZHAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap